J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning
Countries May Impose Age Restrictions
Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.
You may also be interested in...
The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.